NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Up 3.5% – Here’s Why

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) rose 3.5% on Friday . The company traded as high as $1.13 and last traded at $1.11. Approximately 80,173 shares changed hands during trading, a decline of 43% from the average daily volume of 141,835 shares. The stock had previously closed at $1.07.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

NeuroSense Therapeutics Trading Up 3.5 %

The stock has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $1.11. The company has a market cap of $15.14 million, a price-to-earnings ratio of -1.73 and a beta of 1.27.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Institutional Trading of NeuroSense Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its holdings in shares of NeuroSense Therapeutics by 40.9% in the third quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock valued at $58,000 after purchasing an additional 13,346 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics during the 4th quarter valued at $78,000. Finally, Citadel Advisors LLC grew its holdings in shares of NeuroSense Therapeutics by 640.9% during the 4th quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock valued at $305,000 after acquiring an additional 219,717 shares in the last quarter. 1.04% of the stock is currently owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.